New stock news | Truly Biological submits four times to Hong Kong Exchange

According to the Hong Kong Stock Exchange disclosed on May 29th, Truebio Limited (referred to as Truebio) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC as its exclusive sponsor. This is the company's fourth time applying for listing on the Hong Kong Stock Exchange, having previously submitted applications on August 4, 2022, February 18, 2025, and November 9, 2025. The prospectus shows that Truebio is a biotechnology company founded in 2012 with a focus on innovative research and development, specializing in the development, production, and commercialization of innovative drugs for the treatment of viral infections, tumors, and cardiovascular and cerebrovascular diseases. The company has built a comprehensive drug portfolio, including seven candidate drugs (including three core products). The company has established a comprehensive research and development platform, including a high-selectivity novel nucleoside broad-spectrum anticancer drug research platform, a TOP01 inhibitor and XDC drug research platform, a drug target discovery and validation platform, and an innovative drug design and optimization platform.